Here's what Found's program is built on: - Lower doses of GLP-1s provide metabolic benefits with improved tolerability (Nature, 2025) - 94% reduction in diabetes progression in people with prediabetes (NEJM, 2017) - Improved insulin sensitivity in PCOS (Reproductive Sciences, 2022) - Cardiovascular benefits independent of weight (Annals of Internal Medicine, 2024) - Reduction in systemic inflammation (Cells, 2024) Our approach: Apply these research insights to early intervention, informed also by clinical practice and real-world patient outcomes
Key Research Attributes Premium dual-peptide research blend: BPC-157 + TB-500 (10mg + 10mg) Studied extensively in tissue repair, healing, and regenerative biology research Explored deeply in systemic cell migration, angiogenesis, and deep tissue remodeling Investigated for connective tissue, tendon, ligament, and recovery-focused models Premium lyophilized format for maximum structural stability, shelf life, and measurement precision Intended strictly for in-vitro and controlled laboratory research use The BPC-157 + TB-500 combination continues to attract unprecedented interest within the global scientific community due to its highly complementary mechanisms and incredibly broad applicability in regenerative research
Tirzepatide reacts to temperature shifts, and wrong storage conditions might lower how well it works
Made in Thailand and FDA certified
The study, published in the Journal of Clinical Investigation Insight , showed that each time overweight mice stopped and restarted GLP-1s, they dropped less and less weight compared to their original weight loss
